TY - JOUR
T1 - Osteogenic protein-1 reduces intercellular adhesion molecule-1 messenger RNA expression, infarct size and TUNEL-positive cardiomyocytes in ischemia/reperfusion rat hearts
AU - Hayashi, Junichi
AU - Kusachi, Shozo
AU - Murakami, Takashi
AU - Miyoshi, Tohru
AU - Nakamura, Keigo
AU - Koten, Kazuya
AU - Ogawa, Hiroko
AU - Hirohata, Satoshi
AU - Ninomiya, Yoshifumi
AU - Shiratori, Yasushi
PY - 2003/12/1
Y1 - 2003/12/1
N2 - Background: Osteogenic protein, a member of the transforming growth factor-beta superfamily, has been reported to decrease the expression of intercellular adhesive molecules and prevent neutrophil accumulation and activity in tissue injury. Objective: To examine the effects of osteogenic protein on ischemia/reperfusion in rat hearts. Methods: Reperfusion was established after a 90 min ligation of the proximal left coronary artery in rats. Recombinant human osteogenic protein-1 (200 μg/kg) was administered via the femoral vein just before reperfusion. Intercellular adhesion molecule-1 (ICAM-1) messenger RNA (mRNA) expression and infarct size were evaluated using Northern blotting and triphenyl tetrazolium chloride staining, respectively. Terminal deoxynucleotidyl transferase mediated biotin-16-2′-deoxyuridine-5′-triphosphate nick end labeling (TUNEL) staining was also performed. Results: In osteogenic protein-1 treated rats, the expression of ICAM-1 mRNA in ischemia/reperfusion hearts rapidly increased 4 h after reperfusion, although, the increase was lower than that observed in the vehicle-treated hearts (7.4±1.6-old versus 14.6±3.7-fold increase compared to the increase observed in preligation control hearts, respectively). Similarly, in day 1 and day 7 hearts, the increase in ICAM-1 mRNA expression was significantly lower in ischemia/reperfusion hearts from rats treated with osteogenic protein-1 than in vehicle-treated rats (2.5±0.1-fold versus 5.8±2.3-fold and 1.5±0.3-fold versus 3.5±0.2-fold, respectively). Infarct size in rats treated with osteogenic protein-1 was significantly smaller than that observed in rats treated with vehicle (13.1±1.2% versus 28.5±5.7% of the left ventricle, P<0.01). The percentage of TUNEL-positive cardiomyocytes in ischemia/reperfusion hearts in rats treated with osteogenic protein-1 was significantly lower than in rats treated with vehicle (17.1±5.3% versus 31.1±4.5%, P< 0.01). Conclusion: The present study demonstrated that recombinant human osteogenic protein-1 suppressed ICAM-1 mRNA expression, reduced infarct size and decreased TUNEL-positive cardiomyocytes in ischemic/reperfused rat hearts.
AB - Background: Osteogenic protein, a member of the transforming growth factor-beta superfamily, has been reported to decrease the expression of intercellular adhesive molecules and prevent neutrophil accumulation and activity in tissue injury. Objective: To examine the effects of osteogenic protein on ischemia/reperfusion in rat hearts. Methods: Reperfusion was established after a 90 min ligation of the proximal left coronary artery in rats. Recombinant human osteogenic protein-1 (200 μg/kg) was administered via the femoral vein just before reperfusion. Intercellular adhesion molecule-1 (ICAM-1) messenger RNA (mRNA) expression and infarct size were evaluated using Northern blotting and triphenyl tetrazolium chloride staining, respectively. Terminal deoxynucleotidyl transferase mediated biotin-16-2′-deoxyuridine-5′-triphosphate nick end labeling (TUNEL) staining was also performed. Results: In osteogenic protein-1 treated rats, the expression of ICAM-1 mRNA in ischemia/reperfusion hearts rapidly increased 4 h after reperfusion, although, the increase was lower than that observed in the vehicle-treated hearts (7.4±1.6-old versus 14.6±3.7-fold increase compared to the increase observed in preligation control hearts, respectively). Similarly, in day 1 and day 7 hearts, the increase in ICAM-1 mRNA expression was significantly lower in ischemia/reperfusion hearts from rats treated with osteogenic protein-1 than in vehicle-treated rats (2.5±0.1-fold versus 5.8±2.3-fold and 1.5±0.3-fold versus 3.5±0.2-fold, respectively). Infarct size in rats treated with osteogenic protein-1 was significantly smaller than that observed in rats treated with vehicle (13.1±1.2% versus 28.5±5.7% of the left ventricle, P<0.01). The percentage of TUNEL-positive cardiomyocytes in ischemia/reperfusion hearts in rats treated with osteogenic protein-1 was significantly lower than in rats treated with vehicle (17.1±5.3% versus 31.1±4.5%, P< 0.01). Conclusion: The present study demonstrated that recombinant human osteogenic protein-1 suppressed ICAM-1 mRNA expression, reduced infarct size and decreased TUNEL-positive cardiomyocytes in ischemic/reperfused rat hearts.
KW - Apoptosis
KW - Inflammation
KW - Ischemic heart disease
KW - Matrix protein
KW - Molecular biology
UR - http://www.scopus.com/inward/record.url?scp=3142752882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142752882&partnerID=8YFLogxK
M3 - Article
C2 - 19649220
AN - SCOPUS:3142752882
SN - 1205-6626
VL - 8
SP - 195
EP - 200
JO - Experimental and Clinical Cardiology
JF - Experimental and Clinical Cardiology
IS - 4
ER -